vimarsana.com
Home
Live Updates
Study Data from Castle Biosciences' Collaboration with the N
Study Data from Castle Biosciences' Collaboration with the N
Study Data from Castle Biosciences' Collaboration with the National Cancer Institute's SEER Program Registries Published in JCO Precision Oncology
Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes
Related Keywords
United States ,
American ,
Matthew Goldberg ,
Derek Maetzold ,
Castle Biosciences ,
Linkedin ,
Castle Biosciences Inc ,
Program Registries ,
American Joint Committee On Cancer Eighth Edition ,
Nasdaq ,
Twitter ,
Facebook ,
Securities Exchange ,
Instagram ,
American Joint Committee ,
Cancer Eighth Edition ,
Decisiondx Melanoma ,
Mypath Melanoma ,
Securities Act ,
Securities Exchange Act ,
Quarterly Report ,
Gene Expression Profile Testing ,
Cutaneous Melanoma ,
Survival Outcomes ,
Population Based Analysis ,